In vivo efficacy of the ketolide ABT-773 (cethromycin) against enterococci in a mouse peritonitis model

Suresh R. Pai, Kavindra V. Singh, Barbara E. Murray

Research output: Contribution to journalArticlepeer-review

Abstract

Using six Enterococcus faecalis and five Enterococcus faecium strains, the ketolide ABT-773 (ABT), now known as cethromycin, was found to have in vivo efficacy against both erythromycin (ERY)-susceptible (Erys) and -intermediate (Eryi) enterococci (ABT 50% protective doses [PD50s], 0.5 to 4.1 and 10.3 to 16.2 mg/kg of body weight, respectively). Against four highly Ery-resistant (Eryr) strains for which ABT MICs were low, ABT showed much greater activity (PD50, 6.3 to 32.5 mg/kg) than ERY (PD50, >200 mg/kg) but was not protective for strains for which ABT MICs were high. In conclusion, ABT-773 showed in vivo efficacy and considerably greater activity than ERY in a mouse peritonitis model.

Original languageEnglish (US)
Pages (from-to)2706-2709
Number of pages4
JournalAntimicrobial Agents and Chemotherapy
Volume47
Issue number8
DOIs
StatePublished - Aug 1 2003

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'In vivo efficacy of the ketolide ABT-773 (cethromycin) against enterococci in a mouse peritonitis model'. Together they form a unique fingerprint.

Cite this